EUVIMEDEUVIMED entdecken
Crossref

Personalization of heparin therapy in bariatric patients using thrombodynamic testing

A. G. Kitaryan, A. A. Orekhov, M. V. Gulyan, K. V. Lobastov, K. S. Veliev, A. S. Egorova, A. G. Osmanian, V. V. Ksenofontov, A. S. Gasparian, A. D. Studenikin, A. I. Dyuzhikov, V. P. Evdokimov und 2 weitere

Ambulatornaya khirurgiya = Ambulatory Surgery (Russia) · 23.07.2026

DOI: 10.21518/akh2026-025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ambulatornaya khirurgiya = Ambulatory Surgery (Russia), online erschienen am 23.07.2026. Verfasst von A. G. Kitaryan und 13 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Morbid obesity is associated with a high risk of venous thromboembolic complications (VTE) after bariatric surgery; however, standard risk stratification scales do not always provide sufficient predictive accuracy for this patient population, and monitoring the efficacy of anticoagulant prophylaxis remains challenging.

Aim

To evaluate the use of thrombodynamics assay for assessing the risk of VTE in patients with morbid obesity undergoing bariatric surgery, stratified according to the modified Caprini-B score, and to analyze the dynamics of hemostasis parameters during anticoagulant prophylaxis. Materials and methods. A prospective observational study included 113 patients with morbid obesity (BMI 44.5 ± 8.0 kg/m2) who underwent laparoscopic bariatric procedures. Patients were divided into two groups: moderate risk (7–11 points on the Caprini-B score, n = 63) and high risk (≥12 points, n = 50). VTE prophylaxis was performed with nadroparin calcium (38–57 anti-Xa IU/kg) for at least 21 days. Thrombodynamics assay was performed before surgery, immediately after surgery, and on postoperative day 4.

Results

No clinically significant VTE events were registered in either group. In high-risk patients, baseline hypercoagulation was detected (clot growth velocity V – 33.0 ± 2.5 μm/min vs. normal range 20–29 μm/min, p < 0.05), which increased after surgery. By day 4, nadroparin therapy achieved normocoagulation in the moderate-risk group; in the high-risk group, hypercoagulation decreased and stabilized at the upper limit of normal. No hemorrhagic complications were observed.

Conclusions

Thrombodynamics assay provides an objective assessment of hemostasis in bariatric patients and enables monitoring of anticoagulant prophylaxis efficacy. The most informative parameters are clot growth velocity and clot size (V, Vst, CS). In patients with ≥12 points on the Caprini-B score, hypercoagulation persists at the upper normal limit by day 4, which may require extended or intensified anticoagulant therapy

Zitieren

APA

Kitaryan, A. G., Orekhov, A. A., Gulyan, M. V., Lobastov, K. V., Veliev, K. S., Egorova, A. S., Osmanian, A. G., Ksenofontov, V. V., Gasparian, A. S., Studenikin, A. D., Dyuzhikov, A. I., Evdokimov, V. P., Potokova, Z. I., & Razumova, K. N. (2026). Personalization of heparin therapy in bariatric patients using thrombodynamic testing. Ambulatornaya khirurgiya = Ambulatory Surgery (Russia). https://doi.org/10.21518/akh2026-025

Vancouver

Kitaryan AG, Orekhov AA, Gulyan MV, Lobastov KV, Veliev KS, Egorova AS, et al. Personalization of heparin therapy in bariatric patients using thrombodynamic testing. Ambulatornaya khirurgiya = Ambulatory Surgery (Russia). 2026. doi:10.21518/akh2026-025

BibTeX
@article{Kitaryan2026,
  author = {Kitaryan, A. G. and Orekhov, A. A. and Gulyan, M. V. and Lobastov, K. V. and Veliev, K. S. and Egorova, A. S. and Osmanian, A. G. and Ksenofontov, V. V. and Gasparian, A. S. and Studenikin, A. D. and Dyuzhikov, A. I. and Evdokimov, V. P. and Potokova, Z. I. and Razumova, K. N.},
  title = {Personalization of heparin therapy in bariatric patients using thrombodynamic testing},
  journal = {Ambulatornaya khirurgiya = Ambulatory Surgery (Russia)},
  year = {2026},
  doi = {10.21518/akh2026-025}
}
Kostenlos starten →